Detroit Police Department officials addressed City Council about the department's policies on interacting with federal immigration officials.

The FDA added a boxed warning to capecitabine and 5-FU labels, noting the risk of serious adverse reactions or death in patients with complete DPD deficiency. According to the safety alert, patients ...

The FDA added a boxed warning to capecitabine and 5-FU labels, noting the risk of serious adverse reactions or death in patients with complete DPD deficiency. Capecitabine and 5-FU are both nucleoside ...

Boxed warning highlights early-onset, potentially fatal fluoropyrimidine toxicity in complete DPD deficiency and recommends avoiding capecitabine or 5-FU in these patients. Pre-treatment DPYD ...

The FDA has updated the product labeling of capecitabine (Xeloda, Genentech) and fluorouracil to reflect the risks of acute toxicity and potentially fatal adverse reactions in patients with ...

Oncology specialists should inform patients about a risk of serious toxicity related to dihydropyrimidine dehydrogenase (DPD) deficiency and should test for DPYD variants before starting treatment ...

FDA strengthens capecitabine and 5‑FU labels: DPD deficiency can trigger fatal toxicity; consider testing, lower doses, and prompt antidote. The FDA has updated the safety labeling for the ...

FDA labeling now recommends DPYD variant testing before initiating capecitabine or 5-FU, except when immediate treatment is clinically necessary. Complete DPD deficiency markedly impairs 5-FU ...